This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Meanwhile, China has firmly established itself as Brazils top trading partner, increasing its foreign direct investment (FDI) to nearly $601 billion by 2023, while India is gaining ground in sectors ranging from energy to pharmaceuticals. billion) in acquisitions and operations across Brazil, where half of its operations are now concentrated.
“One is the high concentration of value, and also the ever-increasing business interruption element of the claim. The pharmaceutical sector is another one where liability claims can be very significant, so it’s very different scenarios for different sectors.”
Consequently, I will concentrate this post on how this crisis is playing out in markets, and the effects it has had, so far, on businesses and investments, and whether these effects are likely to be transient or permanent.
Consequently, I will concentrate this post on how this crisis is playing out in markets, and the effects it has had, so far, on businesses and investments, and whether these effects are likely to be transient or permanent.
Bernstein told Webster that Freebird has been implemented across a wide range of companies – from the Fortune 500 to relatively small start-ups – and across a wide variety of verticals, including education, manufacturing, pharmaceuticals and technology. “If So, we’ve concentrated our resources here.”. So, how does it work?
Even a cursory examination of the the Nifty Fifty , the stocks that drove US equities upwards in the early 1970s, reveals companies like Coca Cola and Gilette, where brand name was a significant contributor to value, as well as pharmaceutical companies like Bristol-Myers and Pfizer, which derived a large portion of their value from patents.
Low price stock has historically had some very large concentrated positions. And those concentrated positions happen because they have high conviction that they’re in that group where it’s not stupid to think about where earnings will be 10 years out. This is what’s wrong with concentrating in the wrong stocks.
Because going back to our thematic investing, our portfolio is 80 percent concentrated in warehouses, rental housing, lab office space and hospitality asset. Like, if you think about — when I was growing up, all of the big pharmaceutical companies had these corporate campuses that were highly securitized, deep in suburbs.
You have a concentrated securities position, right? If you’re picking a job today, I understand the hot jobs are in finance and pharmaceuticals but, you know, you have to think through the duration of your career, right? So, he’s going to do a CFO rotation at one of the large pharmaceutical companies.
I was particularly, I was in, I was working in, on the East coast and, you know, any, everything from like pharmaceutical to automotive to, to what a, what a distribution network looked like. One is just generally on the valuation question with technology and similarly, the market concentration of the magnificent seven.
However, attempts at disruption, whether it be from Mark Cubans pharmaceutical start-up or from Google and Amazons health care endeavors, have largely left the system intact. The clearest loser from disruption is the status quo.
We organize all of the trending information in your field so you don't have to. Join 39,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content